Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 5

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 5
---
 as issued by the International Accounting Standards Board, or the IASB. None of the financial
statements were prepared in accordance with generally accepted accounting principles in the United States.

On September 30, 2022, we effected a one-for-30
consolidation of our issued and outstanding common shares. In addition, on November 28, 2023, we effected a one-for-30 consolidation of
our issued and outstanding common shares. Except where otherwise indicated, all share and per share data in this prospectus supplement
have been retroactively restated to reflect the aforementioned consolidations.

<div align='center'>i

PROSPECTUS SUMMARY</div>

This summary highlights information contained elsewhere in or incorporated by reference into this prospectus that we consider important. This summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the “Risk Factors” section and the financial statements and related notes incorporated by reference into this prospectus and the other documents incorporated by reference into this prospectus, which are described under “Incorporation by Reference” before making an investment in our securities.

Company Overview

We are a clinical pharmaceutical company currently
engaged in phase I/IIa clinical trials of novel psychedelic medicines to solve widespread, yet under-served, health problems. Our goal
is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders, where
there is significant unmet need and lack of innovation. We see psychedelic therapies, which previously may have been overlooked or underused,
as the future of treatment for a variety of indications. We believe that our solution for AUD can help solve one of the world’s
biggest health problems, which costs the United States alone roughly $250 billion each year.

Our flagship treatment and focus for the short
term is on AUD, which is incredibly common. It varies from mild to excessive and describes a person’s inability to restrict their
alcohol consumption, despite negative social, occupational, or health consequences. Alcohol consumption contributes to 3 million deaths
each year globally and is the third most common preventable cause of death in the United States. In January 2025, the U.S. Surgeon General
released a new Surgeon General’s Advisory on Alcohol and Cancer Risk, outlining the direct link between alcohol consumption and
increased cancer risk, which is in addition to other common risks associated with excessive